Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navitoclax in Relapsed/Refractory CLL
NCT00481091Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2007
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of navitoclax in chronic lymphocytic leukemia (CLL), sponsored by AbbVie Inc.. Started Jul 2007; status: completed.
02
Drugs
navitoclax
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00481091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00481091.